NCT04083976 2026-03-19
RAGNAR
Janssen Research & Development, LLC
Phase 2 Active not recruiting
Clinical Trials
28 trialsNCT06009926 2026-03-19
Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06360588 2026-03-19
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06126276 2026-03-18
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06136897 2026-03-18
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06351371 2026-03-18
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07480733 2026-03-18
A Phase II Clinical Study Evaluating the Safety, Tolerability,Pharmacokinetics, and Preliminary Efficacy of JS212 andJS213 as Monotherapy and in Combination in Patients Withadvanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Not yet recruiting
NCT05023655 2026-03-17
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Prisma Health-Upstate
Phase 2 Terminated
NCT06581432 2026-03-17
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Boehringer Ingelheim
Phase 2 Recruiting
NCT06654050 2026-03-17
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT06840834 2026-03-16
Bi-MAPS
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Recruiting
NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07018622 2026-03-11
DAPA-ARMOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2 Recruiting
NCT07111546 2026-03-11
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT07196644 2026-03-11
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
AbbVie
Phase 2 Recruiting
NCT07459920 2026-03-10
CAPTURE
National Cancer Institute, Naples
Phase 2 Not yet recruiting
NCT07331155 2026-03-09
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT01761929 2026-03-06
5fr SBRT
University Health Network, Toronto
Phase 2 Completed
NCT04589845 2026-03-06
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
Phase 2 Recruiting
NCT07172919 2026-03-06
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Amgen
Phase 2 Recruiting
NCT01843374 2026-03-05
Tremelimumab
MedImmune LLC
Phase 2 Active not recruiting
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT05960773 2026-03-04
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Suspended
NCT07246863 2026-03-04
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
Phase 2 Recruiting
NCT07450352 2026-03-04
SEED-CRYO: Sequential 125I Seed Implantation Followed by Cryoablation vs Single-Modality Local Therapy in Unresectable Solid Tumors
Jinan Military General Hospital
Phase 2 Not yet recruiting
NCT07028281 2026-03-03
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT06410209 2026-02-27
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
Children's Oncology Group
Phase 2 Recruiting
NCT07437625 2026-02-27
Lesion-Allocated Therapy for Multiple Metastases and Tumor-Zoned Treatment for Bulky Tumors: A Phase II Study of Iodine-125 Seed Implantation Combined With Cryoablation in High-Burden Metastatic Disease
Jinan Military General Hospital
Phase 2 Not yet recruiting